Leadership Overview
Vertex has 10 executives leading key functions including strategy, human resources, marketing, and research.
Driven by innovation, Vertex develops and commercializes medicines for serious diseases with significant unmet medical needs, impacting patients worldwide through advanced biotechnology.
Driven by innovation, Vertex develops and commercializes medicines for serious diseases with significant unmet medical needs, impacting patients worldwide through advanced biotechnology.
Leadership Roles at Vertex
Md Reshma Kewalramani - Chief Executive Officer & President
Md Reshma Kewalramani, the Chief Executive Officer & President at Vertex, directs the company's overall strategy and operational execution. This leadership role involves guiding Vertex's mission to develop and commercialize transformative medicines for serious diseases with significant unmet medical needs. Kewalramani oversees the advancement of research programs in areas such as kidney disease, type 1 diabetes, and myotonic dystrophy, ensuring alignment with the company's long-term vision. The Chief Executive Officer & President drives the expansion of Vertex's therapeutic portfolio, which currently includes treatments for cystic fibrosis, sickle cell disease, and transfusion-dependent beta thalassemia. This executive ensures that Vertex's scientific innovation translates into tangible patient benefit, reaching individuals through a global network of healthcare providers, specialty pharmacies, hospitals, and distributors. Md Reshma Kewalramani's leadership focuses on fostering a culture of scientific excellence and patient-centricity, positioning Vertex at the forefront of biotechnology advancements and solidifying its market impact.
Stephanie Franklin - Senior VP & Chief Human Resources Officer
Stephanie Franklin, the Senior VP & Chief Human Resources Officer at Vertex, architects the company's human capital strategy and organizational development. This critical function ensures Vertex attracts, retains, and develops top talent essential for advancing its mission of creating medicines for serious diseases. Franklin oversees all aspects of human resources, including talent acquisition, compensation and benefits, employee relations, and diversity and inclusion initiatives. The Senior VP & Chief Human Resources Officer plays a pivotal role in shaping Vertex's culture, fostering an environment that supports scientific innovation and patient focus. This leadership position involves close collaboration with other executives to align workforce capabilities with strategic business objectives, particularly in research programs targeting kidney disease, type 1 diabetes, and other genetic disorders. Stephanie Franklin's oversight extends to ensuring HR policies and practices support the global reach of Vertex's therapies, serving patients worldwide through various healthcare channels. Franklin's strategic direction enhances organizational effectiveness and employee engagement, crucial for Vertex's continued success in the biotechnology sector.
Stephanie Franklin (she/her/hers) - Senior VP & Chief Human Resources Officer, Vertex Pharmaceuticals
Stephanie Franklin, the Senior VP & Chief Human Resources Officer, Vertex Pharmaceuticals at Vertex, drives the strategic implementation of human resources initiatives across the organization. This role focuses on cultivating a robust talent pipeline and fostering a high-performance culture that supports Vertex's commitment to developing breakthrough therapies for serious diseases. Franklin manages comprehensive HR operations, including talent management, organizational design, and employee engagement programs, ensuring alignment with the company's scientific and commercial goals. The Senior VP & Chief Human Resources Officer, Vertex Pharmaceuticals collaborates with executive leadership to translate business strategy into effective people solutions, particularly for research and development efforts in areas like cystic fibrosis and sickle cell disease. This position is instrumental in ensuring Vertex's global workforce is equipped to meet the challenges of bringing innovative medicines to patients worldwide. Stephanie Franklin's leadership ensures that Vertex's most valuable asset—its people—are empowered to achieve the company's ambitious objectives in biotechnology and patient care.
Tatum Murray - Senior Director, Chief of Staff To the Chief Patient and External Affairs Officer
Tatum Murray, the Senior Director, Chief of Staff To the Chief Patient and External Affairs Officer at Vertex, provides strategic support and operational leadership to enhance patient engagement and external communications. This role is crucial for ensuring Vertex's patient-centric approach is effectively integrated into its external affairs strategy, particularly for therapies addressing serious diseases. Murray manages key initiatives that bridge patient needs with Vertex's development and commercialization efforts, including programs for cystic fibrosis and sickle cell disease. The Senior Director, Chief of Staff To the Chief Patient and External Affairs Officer facilitates cross-functional collaboration between patient advocacy groups, regulatory bodies, and internal teams to amplify patient voices. This position ensures that Vertex's external messaging accurately reflects its commitment to patients and its scientific advancements. Tatum Murray's operational oversight supports the Chief Patient and External Affairs Officer in navigating complex stakeholder relationships and driving impactful outreach programs worldwide. Murray's contributions are vital for strengthening Vertex's reputation and ensuring its medicines reach those who need them most.
Colleen O'Brien - Toxicology Research Senior Scientist & Chief Revenue Officer, Study Monitor
Colleen O'Brien, the Toxicology Research Senior Scientist & Chief Revenue Officer, Study Monitor at Vertex, bridges critical scientific research with revenue generation oversight. This unique dual role focuses on ensuring the scientific integrity of toxicology studies while also driving commercial success for Vertex's therapeutic innovations. O'Brien's responsibilities include monitoring study progress and financial performance, ensuring that research into serious diseases aligns with market viability. The Toxicology Research Senior Scientist & Chief Revenue Officer, Study Monitor contributes to Vertex's portfolio of medicines for conditions such as cystic fibrosis and sickle cell disease by ensuring rigorous scientific validation and effective market penetration strategies. This executive's oversight ensures that Vertex's investments in research and development translate into sustainable revenue streams, supporting the company's mission to serve patients globally. Colleen O'Brien's expertise in both scientific research and revenue management is essential for Vertex's continued growth and its ability to deliver life-changing treatments.
Erin Connors - Senior Director, Chief of Staff To the Chief Regulatory and Quality Officer
Erin Connors, the Senior Director, Chief of Staff To the Chief Regulatory and Quality Officer at Vertex, ensures operational excellence and strategic alignment within regulatory and quality assurance functions. This role is paramount in maintaining Vertex's adherence to global standards for developing and commercializing medicines for serious diseases. Connors supports the Chief Regulatory and Quality Officer in navigating complex regulatory landscapes and upholding the highest quality benchmarks for Vertex's portfolio, including therapies for cystic fibrosis and sickle cell disease. The Senior Director, Chief of Staff To the Chief Regulatory and Quality Officer facilitates seamless communication and execution across departments, ensuring that all product development and manufacturing processes meet stringent requirements. This position is critical for expediting the delivery of Vertex's innovative treatments to patients worldwide. Erin Connors's focus on operational efficiency and compliance safeguards Vertex's reputation and its ability to bring safe and effective medicines to market, reinforcing the company's commitment to patient well-being.
Katie Noon - Chief of Staff & Director
Katie Noon, the Chief of Staff & Director at Vertex, provides strategic operational support and drives key initiatives across various functions. This role is integral to ensuring the efficient execution of Vertex's mission to develop and commercialize medicines for serious diseases with significant unmet medical needs. Noon collaborates closely with executive leadership to streamline operations, enhance cross-functional collaboration, and advance strategic priorities, including research programs in kidney disease and type 1 diabetes. The Chief of Staff & Director plays a vital part in translating high-level objectives into actionable plans, ensuring that Vertex's efforts in areas like cystic fibrosis and sickle cell disease progress effectively. This position supports the coordination of resources and the implementation of best practices across the organization. Katie Noon's leadership ensures that Vertex maintains agility and focus in its pursuit of delivering life-changing therapies to patients globally, reinforcing the company's commitment to scientific innovation and patient care.
Robert Kauffman - Senior Vice President and Chief Marketing Officer
Robert Kauffman, the Senior Vice President and Chief Marketing Officer at Vertex, directs the company's global marketing strategies and brand development. This leadership position is essential for communicating the value of Vertex's innovative medicines for serious diseases to healthcare providers, patients, and stakeholders worldwide. Kauffman oversees the creation and execution of marketing campaigns that highlight the scientific advancements and patient benefits of Vertex's portfolio, including therapies for cystic fibrosis and sickle cell disease. The Senior Vice President and Chief Marketing Officer ensures that Vertex's market presence effectively supports its mission to address significant unmet medical needs. This role involves deep collaboration with commercial, medical affairs, and R&D teams to align marketing efforts with product development and patient access strategies. Robert Kauffman's expertise drives market penetration and brand recognition, crucial for Vertex's continued growth and its ability to reach patients globally with life-changing treatments.
Olivia Green - Director, Chief of Staff, North America Commercial
Olivia Green, the Director, Chief of Staff, North America Commercial at Vertex, drives strategic execution and operational efficiency within the North American commercial division. This role is critical for ensuring Vertex's therapies for serious diseases are effectively delivered to patients across the region. Green supports the North America Commercial leadership in implementing go-to-market strategies, optimizing sales performance, and enhancing market access for Vertex's portfolio, including treatments for cystic fibrosis and sickle cell disease. The Director, Chief of Staff, North America Commercial facilitates cross-functional alignment between commercial teams, medical affairs, and other key departments to maximize patient reach and support. This position is instrumental in translating business objectives into tangible results within the dynamic North American market. Olivia Green's leadership ensures that Vertex's commercial operations in North America are robust and responsive, contributing significantly to the company's mission of serving patients with unmet medical needs.
Rashmi Sarnaik - Director, Chief of Staff To the Head of Medical Affairs
Rashmi Sarnaik, the Director, Chief of Staff To the Head of Medical Affairs at Vertex, provides strategic operational leadership to advance Vertex's medical affairs initiatives. This role is vital for ensuring that Vertex's scientific and clinical expertise effectively supports its mission to develop medicines for serious diseases. Sarnaik collaborates with the Head of Medical Affairs to drive key projects, enhance communication across medical teams, and ensure alignment with global medical strategies for Vertex's therapeutic areas, such as cystic fibrosis and sickle cell disease. The Director, Chief of Staff To the Head of Medical Affairs facilitates the execution of medical education programs, scientific exchange, and data dissemination to healthcare professionals worldwide. This position is crucial for translating scientific insights into patient benefit and supporting the responsible commercialization of Vertex's innovations. Rashmi Sarnaik's contributions ensure that Vertex's medical affairs function operates with maximum impact and efficiency, reinforcing the company's commitment to scientific excellence and patient well-being.
Explore Leadership Teams in Manufacturing
Founded in 2003, Phibro Animal Health Corporation is a global manufacturer and marketer of animal health pharmaceuticals, animal nutrition, and performance products. The company is headquartered in Teaneck, New Jersey.
Company Leadership
AS
LM
DG
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
EB
MM
Founded in 1998, Aldevron is a biotechnology privately held company that develops and manufactures plasmid DNA, proteins, enzymes, and antibodies. Aldevron is located in North Dakota.
Company Leadership MC
LG
JM
Founded in 1988 and headquartered in Westbury, New York, PL Developments is a manufacturer, packager, and distributor of pharmaceutical and consumer healthcare products.
Company Leadership
AS
MS
CN
Frequently Asked Questions Regarding Vertex Top Executives and Leadership Team
